Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . 35 三生 制药 3SBIO INC . ( Incorporated in the Cayman Islands with limited liability ) ( Stock Code : 01530 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026 FINANCIAL HIGHLIGHTS * Notes : 1 Revenue increased by RMB170.5 million or 3.9 % to RMB4,526.0 million , as compared to the six months ended 30 June 2025 . Gross profit increased by RMB78.8 million or 2.1 % to RMB3,794.6 million , as compared to the six months ended 30 June 2025. The gross profit margin decreased to 83.8 % from 85.3 % for the six months ended 30 June 2025 . Net profit attributable to equity shareholders of the Company decreased by RMB211.6 million or 15.6 % to RMB1,146.6 million , as compared to the six months ended 30 June 2025. Net profit attributable to equity shareholders of the Company adjusted for non- operating items ' increased by RMB300.5 million or 26.5 % to RMB1,436.3 million , as compared to the six months ended 30 June 2025 . EBITDA decreased by RMB323.8 million or 17.7 % to RMB1,508.7 million , as compared to the six months ended 30 June 2025. EBITDA adjusted for non - operating items² increased by RMB188.2 million or 11.7 % to RMB1,798.3 million , as compared to the six months ended 30 June 2025 . All numbers in the “ Financial Highlights ” section are subject to rounding adjustments and therefore are approximate numbers only . The net profit attributable to owners of the Company adjusted for non - operating items is defined as the profit attributable to owners of the Company for the period excluding , as applicable ( such excluded items , as applicable , " Excluded Items " ) : a ) the expenses associated with the awarded shares granted by 3SBio Inc. ( " 3SBio ” or the “ Company ” ) in September 2024 ; b ) the expenses associated with the awarded shares granted by Mandi Inc. in October 2025 ; c ) d ) g ) h ) 2 the expenses associated with the awarded shares granted under a restricted share incentive plan by Sunshine Guojian Pharmaceutical ( Shanghai ) Co. , Ltd. ( " Sunshine Guojian ” ) in July 2024 ; the expenses associated with the awarded shares granted under a restricted share incentive plan by Sunshine Guojian in June 2025 ; fair value gains on derivative financial instruments ; fair value gains or losses on financial assets at fair value through profit or loss ( “ FVTPL ” ) ; fair value gains or losses on financial liabilities ; and non - operating foreign exchange differences . The EBITDA adjusted for non - operating items is defined as the EBITDA for the period excluding the Excluded Items . 1